The DTNBP1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product provides a heterogeneous pool of cells with targeted disruption of the DTNBP1 gene, enabling loss-of-function studies in a cancer-relevant background. The polyclonal format captures naturally occurring editing variation across the population, offering a robust starting material for functional screening, pooled assays, and physiologically relevant modeling of dysbindin deficiency.
The A-549 cell line originates from a 58-year-old Caucasian male with lung carcinoma and is widely established as an adherent model for non-small cell lung cancer (NSCLC). The cells harbor a KRAS G12S mutation and exhibit epithelial morphology, making them valuable for investigating oncogenic signaling, drug resistance, and epithelial-mesenchymal transition. This host cell background provides a clinically pertinent context for examining how DTNBP1 loss affects lung adenocarcinoma cell behavior.
DTNBP1 encodes dysbindin, a core subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Dysbindin interacts with BLOC-1 partners including BLOC1S1?CBLOC1S6, as well as dystrobrevin, sorting nexins SNX5/6, AP-3 complex, and DISC1. Functionally, DTNBP1 is regulated by SP1 and NF-Y transcription factors and operates within PI3K/AKT signaling. Its downstream effects involve modulation of LAMP1-positive lysosomal compartments, SNAP-25?Cdependent synaptic vesicle machinery, D2 dopamine receptor trafficking, integrin trafficking, and AKT phosphorylation. Through these interactions, dysbindin coordinates endosomal-lysosomal trafficking and cargo sorting.
In A-549 cells, CRISPR-mediated disruption of DTNBP1 impairs BLOC-1 complex activity, leading to dysregulated endosomal-lysosomal trafficking and altered intracellular protein distribution. This knockout model phenocopies aspects of dysbindin-related pathologies, affecting exosome secretion, cell adhesion, and PI3K/AKT signal transduction. As a consequence, loss of dysbindin can modulate cancer cell proliferation, migration, and invasive potential, making these polyclonal cells a powerful tool for studying the intersection of membrane trafficking and tumorigenesis.
These polyclonal DTNBP1 knockout cells are suitable for a wide range of applications, including lung cancer biology research, intracellular trafficking analysis, CRISPR knockout validation, and exosome characterization. Representative assays include Western blotting for target confirmation, immunofluorescence for LAMP1/2, proliferation and migration/invasion assays, RT-qPCR, flow cytometry, drug sensitivity testing with agents like cisplatin, and transcriptomic profiling via RNA-seq. The polyclonal population also facilitates pooled functional genomics screens and dose-response studies. For further information or support, please contact Ascent Research.
